Robert J Watson

USPTO Granted Patents = 17 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 45(Granted Patents)

Company Filing History:

11 out of 92

Glaxosmithkline Intellectual Property (no.2) Limited

Years Active: 2014-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11319307 - 2,3-dihydrobenzohurans as bromodomain inhibitors (2022-05-03),

2. 11273146 - Benzofuran derivatives and their use as bromodomain inhibitors (2022-03-15),

3. 10966961 - Pyrazole derivatives as bromodomain inhibitors (2021-04-06),

4. 10934272 - Pyridyl derivatives as bromodomain inhibitors (2021-03-02),

5. 10927080 - Pyridinone dicarboxamide for use as bromodomain inhibitors (2021-02-23),

6. 10849897 - Pyridyl derivatives as bromodomain inhibitors (2020-12-01),

7. 10844015 - Pyridine dicarboxamide derivatives as bromodomain inhibitors (2020-11-24),

8. 10583112 - Benzo[b]furans as bromodomain inhibitors (2020-03-10),

9. 10471050 - 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors (2019-11-12),

10. 10428026 - Pyridinone dicarboxamide for use as bromodomain inhibitors (2019-10-01),

11. 10370356 - Pyridinone dicarboxamide for use as bromodomain inhibitors (2019-08-06),

12. 9861627 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2018-01-09),

13. 9610284 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2017-04-04),

14. 9416130 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2016-08-16),

15. 9067936 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor (2015-06-30),

Title: The Innovative Journey of Robert J. Watson

Introduction

Robert J. Watson is a distinguished inventor based in Stevenage, GB. With an impressive portfolio of 17 patents, he has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as bromodomain inhibitors. Watson's work emphasizes the potential of innovative chemical solutions in therapeutic applications.

Latest Patents

Among his most recent inventions are two notable patents. The first patent, titled "2,3-Dihydrobenzohurans as Bromodomain Inhibitors," focuses on compounds of a specific formula and their applications in therapy. This invention highlights the innovative approach to targeting bromodomain proteins, which are implicated in various diseases. The second patent, "Benzofuran Derivatives and Their Use as Bromodomain Inhibitors," shares a similar theme, presenting more compounds and their therapeutic potentials. Both patents underline Watson’s commitment to advancing medical treatments through innovative chemical compositions.

Career Highlights

Throughout his career, Robert J. Watson has been affiliated with prestigious organizations that drive innovation in healthcare. He has notably worked with GlaxoSmithKline Intellectual Property (No.2) Limited and GlaxoSmithKline LLC, where he contributed to cutting-edge research and development. His role in these companies has positioned him at the forefront of pharmaceutical innovation, allowing him to refine his expertise in compound development for therapeutic use.

Collaborations

Collaboration has been a key aspect of Watson's career. He has worked alongside esteemed colleagues, including Emmanuel Hubert Demont and Stephen John Atkinson. These collaborations have fostered a dynamic exchange of ideas and have been instrumental in advancing research projects aimed at creating new therapeutic agents.

Conclusion

Robert J. Watson's achievements in the realm of patenting significant pharmaceutical inventions reflect his dedication to innovation in healthcare. His latest patents demonstrate the potential for his research to translate into tangible medical therapies, showcasing the impact that skilled inventors can have on public health. As he continues to explore new horizons in compound invention, the scientific community eagerly anticipates his future contributions.

This text is generated by artificial intelligence and may not be accurate.